1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,230 | 0,290 | 23:01 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Oncodesign Precision Medicine (OPM): OPM Announces Its 2026 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position | 456 | Business Wire | OPM-201: secured funding from the Michael J. Fox Foundation to support the development of the LARKIN program in Parkinson's disease OPM-101: continued preparation for the REVERT Phase 1b/2a... ► Artikel lesen | |
| 08.10. | Oncodesign Precision Medicine Advances OPM-201 Toward Phase 1b Parkinson's Disease Trial | 3 | pulse2.com | ||
| 07.10. | Oncodesign Precision Medicine: OPM Achieved Several Major Scientific and Regulatory Milestones as Part of the LARKIN Program, Supported With Funding By The Michael J. Fox Foundation for Parkinson's Research (MJFF) | 559 | Business Wire | MJFF confirms its support to the program with the payment of an additional funding tranche Successful micronization of the active pharmaceutical ingredient and manufacturing of the first... ► Artikel lesen | |
| 30.04. | Oncodesign Precision Medicine (OPM): OPM Announces Its 2025 Annual Results and Provides an Update on Its Clinical Developments | 780 | Business Wire | Continued development of OPM-101 with Phase 1 clinical validation and approval to initiate the REVERT study (Phase 1b/2a in oncology) Significant progress with OPM-201: independent validation... ► Artikel lesen | |
| 03.03. | Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson's Disease | 754 | Business Wire | The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson's disease and the execution of long-term toxicology study including... ► Artikel lesen | |
| ONCODESIGN PRECISION MEDICINE Aktie jetzt für 0€ handeln | |||||
| 08.01. | Oncodesign Precision Medicine and Ksilink Join Forces to Test the Nanocyclix Chemical Library in Cell Models Derived From Patients With Serious Central Nervous System Diseases | 511 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant... ► Artikel lesen | |
| 29.12.25 | Oncodesign Precision Medicine and Navigo Proteins Announce the End of Their Collaboration in the Development of Radiotheranostics | 479 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen | |
| 06.11.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.11.2025 | 416 | Xetra Newsboard | Das Instrument ZC0 NO0012780958 STAINL.TANKERS NK 10 EQUITY wird cum Kapitalmassnahme gehandelt am 06.11.2025 und ex Kapitalmassnahme am 07.11.2025 The instrument ZC0 NO0012780958 STAINL.TANKERS NK... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,100 | +0,26 % | EQS-WpÜG: Übernahmeangebot / Zielgesellschaft: Qiagen N.V.; Bieter: Crown NL Bidco B.V. | EQS-WpÜG: Crown NL Bidco B.V. / Übernahmeangebot
Übernahmeangebot / Zielgesellschaft: Qiagen N.V.; Bieter: Crown NL Bidco B.V.
21.10.2026 / 23:30 CET/CEST
Veröffentlichung einer... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 15,360 | -26,89 % | ArriVent BioPharma veröffentlicht Phase-1-Daten für Onkologie-Kandidaten ARR-217 | ||
| KINIKSA PHARMACEUTICALS | 72,98 | -4,89 % | AstraZeneca, Cardiol Therapeutics, Kiniksa - Neue Hoffnung für Herzpatienten | Herz-Kreislauf-Erkrankungen gehören weltweit zu den größten medizinischen Herausforderungen. Während etablierte Pharmakonzerne Milliarden in neue Wirkstoffe und Künstliche Intelligenz investieren, entwickeln... ► Artikel lesen | |
| TANGO THERAPEUTICS | 22,210 | -4,92 % | Wedbush raises Tango Therapeutics stock price target on trial data | ||
| NURIX THERAPEUTICS | 25,550 | +0,83 % | Nurix Therapeutics Swings To Profit In Q3 On Roche Licensing Revenue | SOUTH SAN FRANCISCO (dpa-AFX) - Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 114,84 | +3,68 % | Kymera Therapeutics (NDQ:KYMR) Has Proven It Can Destroy Proteins. Can It Build Blockbuster Medicines? | ||
| ERASCA | 14,985 | +4,03 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| MODERNA | 176,24 | -1,41 % | Sell the News: Warum starke Studiendaten den Moderna-Kurs crashen lassen | Die Moderna-Aktie stürzt trotz starker Studiendaten zum Krebsimpfstoff mit Merck um mehr als 25 Prozent ab. Analysten sehen eine klassische Sell-the-News-Reaktion nach monatelanger Kursrallye. Die Moderna-Aktie... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,500 | 0,00 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| IMMUNOVANT | 28,170 | -0,81 % | Immunovant Inc.: Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 | ||
| RECURSION PHARMACEUTICALS | 3,800 | +2,84 % | Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast | ||
| PRAXIS PRECISION MEDICINES | 267,63 | +5,83 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| DISC MEDICINE | 77,79 | 0,00 % | Jefferies raises Disc Medicine stock price target on drug opportunity | ||
| BIONTECH | 77,50 | -1,52 % | BioNTech SE: BioNTech präsentiert auf dem ESMO-Kongress 2026 Fortschritte ihrer spätklinischen Onkologie-Pipeline und Daten zu innovativen Kombinationsansätzen mit Pumitamig | In einer Late-Breaking-Präsentation werden erste Daten aus der globalen klinischen Phase-2-Studie ROSETTA Lung-107 vorgestellt, in der Pumitamig, ein bispezifischer PD-L1×VEGF-A-Immunmodulatorkandidat... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,790 | -1,08 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen |
Das Unternehmen ONCODESIGN PRECISION MEDICINE SA kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,026 (-9,12 %) liegt der Kurs bei 0,259 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCODESIGN PRECISION MEDICINE SA finden Sie auf Wallstreet Online.